Sacubitril/Valsartan versus enalapril in nonischemic heart failure in Paradigm-Hf trial
Journal Title: Journal of Cardiovascular Medicine and Cardiology - Year 2018, Vol 5, Issue 4
Abstract
Background: We compared the angiotensin receptor–neprilysin inhibitor LCZ696 (sacubitril/valsartan) with enalapril in patients who had nonischemic heart failure with a reduced ejection fraction. Methods: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. Results: The trial was stopped early, according to pre specified rules, after a median follow up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. The ischemic patients were 5036 (60%) patients and non-ischemic patients were 3363 (40%) patients. In ischemic and in non-ischemic group the LCZ696 was superior to enalapril for reduce primary outcome and CV death (P< 0.001). In LCZ696 group: the primary outcome had occurred in 339 patients (20.16 %) in the non-ischemic group and 575 patients (22.9 %) in the ischemic group (P: 0.03). A total of 199 patients (11.8%) in non-ischemic group and 359 patients in ischemic group (14.3%) died from cardiovascular causes (P: 0.01). and no significant difference between in CV death and primary outcome in enalapril group in the ischemic and non-ischemic patients Conclusions: LCZ696 was superior to enalapril in reducing the risks of cardiovascular death and hospitalization for heart failure in ischemic and non-ischemic heart failure.
Authors and Affiliations
Habib Mohammed
Keywords
Related Articles
- EP ID EP523879
- DOI 10.17352/2455-2976.000070
- Views 66
- Downloads 0
Echocardiographic Biatrial Remodelling and Diastolic Function Assessment in Long-Term Follow-Up after Typical Atrial Flutter Ablation
Background: A reverse left atrial (LA) remodelling after atrial fibrillation (AF) ablation has been reported and a relationship between diastolic function and AF is well known. However, there is little information about...
Cardio-diabetology: New subspecialty and collaborative work to defeat the burden of deadly duo
Cardiovascular disease (CVD) is one of the most global threatened diseases; particularly coronary artery disease (CAD) is a major deadly attack around the world. Diabetes mellitus (DM) is associated with a 2 to 4-fold in...
Autonomic Innervation from the Aortic Root Ventricular Ganglionated Plexi to the Pulmonary Vein: A Novel Pathway
Background: Autonomic nerve innervation pathway from the ventricular GP to the pulmonary veins (PV) remains unclear. Aim: This study investigates the autonomic innervations from aortic root ventricular GP to the PVs. Ni...
Nature of Human Gut Microbiome: How do they play in Cardiovascular Disease?
Cardiovascular disease is the number one killer of death around the world. Most of the cardiovascular diseases are caused by sedentary life style, bad eating habit, tobacco smoking, high alcohol intake, dyslipidemia and...
The pathophysiology of chronic cardiorenal disease based on central hemodynamics
As patients with chronic kidney disease (CKD) and chronic heart failure (CHF) increase, there is concern about a future heart failure pandemic. Deterioration of renal function is an independent prognostic factor for CHF...